



Tailored Solutions for Rare

Cardiovascular Disease

Therapeutic Development

 \bigcirc

Contact Us

C

info@protheragen.us

www.protheragen.us/cardiovascular-disease/

1-631-533-2057



Overview

| About Us | 3 |
|----------------------------|----|
| Disease Areas of Focus | 4 |
| Customized Solutions | 5 |
| Therapeutic Development | 6 |
| Disease Model Development | 7 |
| Preclinical Research | 13 |
| Clinical Research Services | 14 |
| Featured Products | 15 |

About Us

01

02

03

04

Your Trusted Preclinical Research Service Provider for Rare Cardiovascular Disease Drug Development

Protheragen is a leading, full-service solutions provider, specializing in the development of drugs and therapies for cardiovascular diseases. We advance and expedite the development of rare cardiovascular disease drugs by offering state-of-the-art solutions and services to innovators globally.

Integrated

A comprehensive suite of services covers every aspect of drug development, ensuring a cohesive approach to research and innovation.

Professional

A team of highly skilled professionals is dedicated to maintaining the highest standards of quality and ethics in all endeavors.

Experienced

With years of expertise and project experience in cardiovascular research, we bring deep knowledge and insights that drive successful outcomes.

Efficient

Optimized processes, cutting-edge technologies, and customized strategies enable swift delivery of results while upholding exceptional quality.





Disease Areas of Focus About Us

Rare cardiovascular diseases encompass a diverse range of conditions that affect the heart and blood vessels, which can include congenital heart defects, rare forms of cardiomyopathy, and specific vascular disorders. Protheragen provides tailored drug development solutions specifically designed for rare cardiovascular disease research across various categories. Our approach combines innovative methodologies and expertise, ensuring that each solution is customized to meet the specific needs of our clients.



Rare Arrhythmias



Rare Cardiac Tumors



Rare Cardiovascular Diseases

Rare Congenital Heart Diseases

Rare Cardiomyopathies







info@protheragen.us

www.protheragen.us/cardiovascular-disease/

Customized Solutions





Therapeutic Development

Our Services

Protheragen offers a one-stop solution for drug discovery and development. By integrating our expertise and cutting-edge technologies, we provide tailored support to accelerate the discovery and development of innovative therapeutics for these challenging conditions.

Diversified Therapeutic Development Platforms



Cardiovascular Diseases

01

Target Identification

Research is conducted to understand rare cardiovascular diseases and identify potential therapeutic targets through molecular studies.

02

Drug Discovery

High-throughput screening is employed to find promising lead compounds and optimize drug candidates with computational tools.

03

In Vitro Studies

Pharmacological properties and mechanisms of potential therapies assessed using advanced *in vitro* models.

04

In Vivo Evaluation

Animal models are utilized to evaluate the efficacy and safety of drug candidates in a complex physiological setting.

Our Services

02

03

Tailored Disease Model Development Services

By leveraging advanced technologies and expertise, **Protheragen** specializes in developing models for rare cardiovascular diseases, providing researchers with essential tools to study these conditions. We create highly customized models that accurately mimic the disease mechanisms, allowing for more effective drug discovery and development.



Cell Line Development

- Primary Cell Development
- iPSC-derived Cell Model Development

Organoid Model Development Service

• 3D Bio-printed Organoids

Self-assembling Organoids

Microfluidic Organ Chips

Tissue-Engineering Models

Animal Model Development Service

- Genetically Engineered Animal Models Surgical Animal Models
- Induced Animal Models

- Transplant Animal Models





Our Services



Organoid Model Development Services

Leveraging advanced 3D culture technology, **Protheragen** has cultivated various organoid types. Our expert team provides tailored organoid model development services to simulate rare cardiovascular diseases, accelerating therapy research and development.

Cardiovascular Organoid Cell Sources

- Induced pluripotent stem cells (iPSCs)
- Embryonic stem cells (ESCs)
- Adult stem cells (ASCs)



3D Bio-printed Organoids

Utilizing 3D bioprinting constructs tissue layer by layer, offering precise control over tissue structure and cell distribution.

Microfluidic Organ Chips

Microfluidic chips feature living cells in microchannels, mimicking human organ structure and nutrient flow.

Self-assembling Organoids

Organoids form from selfassembling stem or organspecific cells into 3D structures reflecting organ function.

Tissue Engineering Models

Tissue engineering combines cells and biomaterials to create constructs that mimic cardiovascular organ anatomy.

Our Services



Organoid Model Development Services



Construction of organoid models

- Multiple cell combinations
- Fully functional
- Validation of organoid models
- H&E staining
- Immunohistochemical staining
- Immunofluorescence staining
- Single-cell sequencing
- Others

Applications

- Mechanism research
- Disease modeling
- Drug screening
- Drug safety evaluation
- Other applications

Case Study of Cardiac Organoid Model Development



Our Services

Animal Model Development Services



Protheragen offers a robust animal model development platform that showcases a diverse array of disease models. This flexibility empowers you to select the most appropriate animal model tailored to your specific research needs, ensuring efficient and reliable studies on rare cardiovascular diseases.



Genetically Engineered

Induced Animal Models

Surgical Animal Models

Transplant Animal

Models

Animal Models for Rare Cardiovascular Disease

- Rare Arrhythmias
- Rare Cardiomyopathies
- Rare Congenital Heart Diseases
- Rare Vascular Diseases
- Rare Cardiac Tumors
- Other Cardiovascular Diseases

Optional Animal Species

- Mouse models
- Rat models
- Rabbit models

- Porcine models
- Zebrafish models
- And more

Our Services



Animal Models for Cardiovascular Diseases

| Model Names | Cardiovascular Diseases | Model Types |
|-----------------------------|---------------------------------------|---------------------------------------|
| Bmpr2-KO Model | Pulmonary Arterial Hypertension (PAH) | Genetically Engineering Model |
| Sugen/Hypoxia-induced Model | Pulmonary Arterial Hypertension (PAH) | Environmental or Stress-induced Model |
| Monocrotaline-induced Model | Pulmonary Arterial Hypertension (PAH) | Chemical-induced Model |
| Kcnh2-KO Model | Long QT Syndrome | Genetically Engineering Model |
| Tbx5-KO Model | Holt-Oram Syndrome | Genetically Engineering Model |
| Scn5a-KO Model | Brugada Syndrome | Genetically Engineering Model |
| Ldlr-KO Model | Familial Hypercholesterolemia (FH) | Genetically Engineering Model |
| HCHF Model | Familial Hypercholesterolemia (FH) | Diet-induced Model |
| Mybpc3-KO Model | Hypertrophic Cardiomyopathy (HCM) | Genetically Engineering Model |
| Myosin-induced Model | Autoimmune Myocarditis | Immunologically-induced model |
| TAC Animal Model | Heart Failure | Surgical Model |

For more information about these or other animal model development services for cardiovascular diseases, please contact us.

Our Services

Case Study of Mybpc3-KO Animal Model Development

Cardiac myosin-binding protein C (cMyBP-C) is a cardiac sarcomeric accessory protein encoded by the *Mybpc3* gene. The *Mybpc3* gene mutation in homozygous mice leads to the development of dilated cardiomyopathy (DCM). Protheragen created a *Mybpc3* knockout mouse model using gene editing techniques to simulate human HCM and DCM. The model specifically deleted exons 2-22 of the *Mybpc3* gene, which results in the absence of the MYBPC3 protein.

Applications of Mybpc3-KO Model

- Screening and efficacy testing of drugs targeting HCM or DCM.
- Research on the mechanisms of diseases related to MYBPC3 deficiencies, such as myocardial hypertrophy and ventricular dilation.



Fig.3 *Mybpc3*^{-/-} mice exhibited decreased ejection fraction (EF) and fractional shortening (FS), alongside increased left ventricular (LV) mass, indicating left ventricular dilation, myocardial hypertrophy, and reduced contractility (Fig.3A-C). Quantitative RT-PCR revealed significant upregulation of fibrosis markers, such as Col1a1 and Col3a1, in *Mybpc3*^{-/-} mice. (Fig.3D).



Preclinical Research

Our Services



As a leading provider of preclinical research services for rare cardiovascular disease drug discovery and development, **Protheragen** offers a variety of tailored solutions to meet the unique needs of our clients.

- ✓ Efficacy Evaluation
- ✓ Safety Assessment
- ✓ Dose Optimization
- ✓ Mechanism of Action Studies
- ✓ Regulatory Compliance

Pharmacodynamics

Pharmacodynamics examines how a drug affects a biological system and influences disease, identifying mechanisms of action and potential side effects in both *in vivo* and *in vitro* settings.



Drug Safety Evaluation

Drug safety evaluation assesses a drug's safety and potential adverse reactions, allowing us to identify and manage safety risks to ensure candidate drug safety.

Pharmacokinetics

Pharmacokinetics studies the absorption, distribution, metabolism, and excretion of a drug, helping to understand its dynamic changes in the body and determine optimal dosage and frequency.

03

01







Clinical Research Services

Our Services

One-stop Investigator Initiated Trial (IIT) Services



Cardiovascular Diseases

Clinical Research Services

- Investigator Initiated Trial (IIT) Services
- Medical Writing Services
- IND/NDA/BLA Application
 Strategy
- Patient Recruitment
- Biostatistics and Programming
- Quality Management Services
- Medical Monitoring Services
- Safety and Pharmacovigilance Services
- Data Management Services
- Project Management Services

Featured Products





Protheragen boasts a wide global network of products, including biofluid samples, tissue samples, cardiovascular system cells, and molecular products. Committed to delivering premium, ethically sourced research materials, we aim to meet the evolving needs of the cardiovascular disease research community.



Biofluid Samples

Biofluid samples are essential for cardiovascular disease diagnostics and therapy development, including various blood components (whole blood and derivatives) and other biofluids.

Tissue Samples

Specializing in superior and diverse normal donor or diseased cardiovascular tissue specimens, we cater to the exacting requirements of scientific inquiry.

Cells of the Cardiovascular System

A range of cardiovascular system cells accurately reflects disease pathology, offering researchers a reliable model for studying cardiovascular conditions.

Molecular Products

Extensive molecular products are available, specifically designed for preclinical research on cardiovascular diseases, including proteins, antibodies, and molecular assay kits.





One-Stop Services for Rare

Cardiovascular Disease Drug

Research and Development

Contact Us

info@protheragen.us

www.protheragen.us/cardiovascular-disease/

kan 1-631-533-2057

101-

101-4 Colin Dr, Holbrook, NY 11741, USA